Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
T. K. De, D. J. Rodman, B. A. Holm, P. N. Prasad & E. J. Bergey. (2003) Brimonidine formulation in polyacrylic acid nanoparticles for ophthalmic delivery. Journal of Microencapsulation 20:3, pages 361-374.
Read now
Read now
Louis B Cantor. (2000) The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous use. Expert Opinion on Pharmacotherapy 1:4, pages 815-834.
Read now
Read now
Robert David. (1998) Changing therapeutic paradigms in glaucoma management. Expert Opinion on Investigational Drugs 7:7, pages 1063-1086.
Read now
Read now
Articles from other publishers (28)
Gita Chawla, Ojasvi Gupta & Tathagata Pradhan. (2023) A Review on Multipurpose Potential of Bioactive Heterocycle Quinoxaline. ChemistrySelect 8:29.
Crossref
Crossref
A. Krishnamanjari Pawar & Chandana Mannepalli. (2022) A Simple and Validated Stability Indicating HPLC Method for
Simultaneous Quantification of Brimonidine, Timolol and
Benzalkonium Chloride in Anti-Glaucoma Ophthalmic Formulations. Asian Journal of Chemistry 35:1, pages 179-186.
Crossref
Crossref
J. Farrando-Pérez, G. Martinez-Navarrete, J. Gandara-Loe, S. Reljic, A. Garcia-Ripoll, E. Fernandez & J. Silvestre-Albero. (2022) Controlling the Adsorption and Release of Ocular Drugs in Metal–Organic Frameworks: Effect of Polar Functional Groups. Inorganic Chemistry 61:47, pages 18861-18872.
Crossref
Crossref
Suresh Kumar Suthar, Narendra Singh Chundawat, Girdhar Pal Singh, José M. Padrón & Yuvraj Kunwar Jhala. (2022) Quinoxaline: A comprehension of current pharmacological advancement in medicinal chemistry. European Journal of Medicinal Chemistry Reports 5, pages 100040.
Crossref
Crossref
Nada M. El Hoffy, Engy A. Abdel Azim, Rania M. Hathout, Marwa A. Fouly & Seham A. Elkheshen. (2021) Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities. European Journal of Pharmaceutical Sciences 158, pages 105648.
Crossref
Crossref
N Cimolai. (2020) A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. Human & Experimental Toxicology 39:10, pages 1279-1290.
Crossref
Crossref
Chun Gwon Park, Goeun Choi, Myung Hun Kim, Se-Na Kim, Hanna Lee, Na Kyeong Lee, Young Bin Choy & Jin-Ho Choy. (2020) Brimonidine–montmorillonite hybrid formulation for topical drug delivery to the eye. Journal of Materials Chemistry B 8:35, pages 7914-7920.
Crossref
Crossref
Benjamin M. Davis, Milena Pahlitzsch, Li Guo, Shiama Balendra, Parth Shah, Nivedita Ravindran, Giulia Malaguarnera, Claudia Sisa, Ehtesham Shamsher, Hisham Hamze, Abdinasir Noor, Acom Sornsute, Satyanarayana Somavarapu & M. Francesca Cordeiro. (2018) Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease. Scientific Reports 8:1.
Crossref
Crossref
Dayse F Sena & Kristina Lindsley. (2017) Neuroprotection for treatment of glaucoma in adults. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Jill M. Sturdivant, Susan M. Royalty, Cheng-Wen Lin, Lori A. Moore, Jeffrey D. Yingling, Carmen L. Laethem, Bryan Sherman, Geoffrey R. Heintzelman, Casey C. Kopczynski & Mitchell A. deLong. (2016) Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorganic & Medicinal Chemistry Letters 26:10, pages 2475-2480.
Crossref
Crossref
Dayse F Sena & Kristina Lindsley. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Prakash Bhagav, Hariom Upadhyay & Sajeev Chandran. (2011) Brimonidine Tartrate–Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation. AAPS PharmSciTech 12:4, pages 1087-1101.
Crossref
Crossref
Prakash Bhagav, Vaibhav Trivedi, Darshan Shah & Sajeev Chandran. (2011) Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma. Drug Delivery and Translational Research 1:2, pages 161-174.
Crossref
Crossref
Dayse F Sena, Kanchan Ramchand & Kristina Lindsley. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
. 2007. Augenheilkunde. Augenheilkunde
309
337
.
Ümit Ubeyt İnan, Sitki Samet Ermis, Ayse Orman, Ersel Onrat, Aylin Yucel, Faruk Ozturk, Ali Asagidag & Atac Celik. (2004) The Comparative Cardiovascular, Pulmonary, Ocular Blood Flow, and Ocular Hypotensive Effects of Topical Travoprost, Bimatoprost, Brimonidine, and Betaxolol. Journal of Ocular Pharmacology and Therapeutics 20:4, pages 293-310.
Crossref
Crossref
PK Sodhi, RM Pandey & SK Ratan. (2003) EFFICACY AND SAFETY OF BRIMONIDINE, DORZOLAMIDE AND LATANOPROST AS ADJUNCTIVE THERAPY IN PRIMARY OPEN ANGLE GLAUCOMA. International Journal of Clinical Practice 57:10, pages 875-878.
Crossref
Crossref
. 2003. Glaucoma Therapy. Glaucoma Therapy
59
61
.
Punita Kumari Sodhi, Lalit Verma & John Ratan. (2014) Dermatological Side Effects of Brimonidine: A Report of Three Cases. The Journal of Dermatology 30:9, pages 697-700.
Crossref
Crossref
Philip F.J Hoyng & Yoshi Kitazawa. (2002) Medical Treatment of Normal Tension Glaucoma. Survey of Ophthalmology 47, pages S116-S124.
Crossref
Crossref
William E Sponsel, Gianmarco Paris, Yolanda Trigo, Melanie Pena, Anke Weber, Keith Sanford & Stuart Mckinnon. (2002) Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. American Journal of Ophthalmology 133:1, pages 11-18.
Crossref
Crossref
Péter Kóthy & G. Holló. (2001) Does glaucoma medication influence the diameter of the retinal arteriole in the human eye?. Acta Physiologica Hungarica 88:3-4, pages 281-292.
Crossref
Crossref
David A. Lee & Jeffrey A. Gornbein. (2001) Effectiveness and Safety of Brimonidine as Adjunctive Therapy for Patients With Elevated Intraocular Pressure in a Large, Open-label Community Trial. Journal of Glaucoma 10:3, pages 220-226.
Crossref
Crossref
Albert J. AugustinAlbert J. Augustin. 2001. Augenheilkunde. Augenheilkunde
291
321
.
Joel S. Schuman. (2000) Antiglaucoma medications: A review of safety and tolerability issues related to their use. Clinical Therapeutics 22:2, pages 167-208.
Crossref
Crossref
Shlomo Melamed & Robert David. (2000) Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three results. Clinical Therapeutics 22:1, pages 103-111.
Crossref
Crossref
David A. Lee. (2000) Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension. Clinical Therapeutics 22:1, pages 53-65.
Crossref
Crossref
G Walters & R H Taylor. (1999) Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye 13:6, pages 797-798.
Crossref
Crossref